GlobalResearch and clinical trials
Light-sensitive molecule tested in the eye for the first time in 6 people with advanced retinitis pigmentosa
A study published in a journal and reviewed by independent scientists. Even so, a single study is not conclusive; it needs to be replicated.
In Australia, a drug was injected into 12 eyes of 6 people with advanced RP. This drug is not gene-specific and is aimed at all types of RP. No serious side effects were seen. There was no inflammation inside the eye. Changes in light perception were observed in some people. Larger studies are needed to assess effectiveness.
What does it mean for patients and families?
This is a very small, early safety study. It has not been shown to improve vision. You can ask your eye doctor (ophthalmologist) about clinical trials.
Source
Scientific paper: Intravitreal photoswitch therapy in advanced retinitis pigmentosa: a phase 1 open-label trial. Nature Medicine, 2026. DOI: 10.1038/s41591-026-04317-6 · PubMed 41981307
The source page was opened and read on October 7, 2026. Summary prepared by the Doktorclub editorial team and translated from Turkish; it has not yet been reviewed by a physician (a scientific board is being set up).
This page is translated from the Turkish original.
Related disease: Retinitis pigmentosa (RP)
This page reports a development; it is not a treatment recommendation. Your doctor decides whether a treatment is right for you.